ArticleBMC nephrology2026
The impact of serum myokine profile on the outcome of peritoneal dialysis patients.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPeritoneal dialysis (PD) patients are at high risk for complications such as muscle loss and peritonitis. Individual myokines and functional assessment of PD patients are inconsistently reported to associate with poor prognosis, but their complex interactions for risk stratification have not been studied.
methodsIn 194 new PD patients, we measured the serum levels of a myokine panel, metabolic and inflammatory markers, together with physical function scores. We employed k-cluster analysis on the result and analyzed patient survival, technique survival, peritonitis-free survival, hospitalisation rate and duration between the patient clusters.
resultsThere are two distinct patient clusters; cluster 1 showed a higher risk profile, with higher Morse Fall Scores, lower Norton scores, lower lean tissue mass, and different myokine levels. Cluster 2 is independently associated with better patient survival (adjusted hazard ratio 0.460, 95% confidence interval [CI] 0.237 to 0.894, p = 0.022) and peritonitis-free survival rate (AHR 0.417, 95% CI 0.205 to 0.846, p = 0.015). Cluster 2 also had lower hospitalisation rate (p = 0.022) and shorter duration of hospital stay (p = 0.014). Individual parameters used for the cluster analysis, however, were not independent predictors.
conclusionA combined assessment of myokine profile and functional status of new PD patients is independently associated with patient survival, peritonitis-free survival, and hospitalization rates. Our results underscore the importance of a comprehensive, integrated approach to patient assessment, which can improve the risk stratification for this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.